医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

STC Life Co., Ltd. Successfully Treats Patients With Parkinson’s Disease at Stem Cell Research and Treatment Center

2014年02月20日 AM12:25
このエントリーをはてなブックマークに追加


 

SEOUL

Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Director: WON JU JUNG) successfully completed mesenchymal stem cell therapy for the patients with Parkinson’s disease, a chronic progressive degenerative disease in nervous system.

Parkinson’s disease is caused when dopamine nerve cells distributed in substance nigra become gradually extinct. It is a chronic progressive degenerative disease characteristically showing quiver, stiffness, bradykinesia and postural instability. General medicine treatment has no effect on Parkinson’s disease and there are no other treatments for it.

97.7 B&H Clinic (Representative Director: WON JU JUNG, www.977bnh.com) administered stem cell into vein of the patients with Parkinson’s disease 3 times every 2 weeks. Mesenchymal stem cell, one of the adult stem cells, is used a lot for neogenesis, and stem cell research institute (Director: SANG YEON LEE) of STC Life Co., Ltd. used stem cells separated from umbilical cord of fetus.

The patients who got stem cell therapy showed remarkable reduction of the symptoms such as lalopathy and paralysis of arms and legs and also showed satisfactory progress to be able to do light exercise. Furthermore, their linguistic ability, visual function and memory have increased and have not shown remarkable deterioration in cognitive function.

According to the result, Chairman KYE HO LEE of STC Life (www.stclife.com) revealed his strong ambitions to push harder to attract overseas patients and domestic patients with hard-to-cure diseases in the future.

It is proven that Mesenchymal stem cell therapy can reduce the symptoms with no adverse effects.

CONTACT

Media contact:
STC Life Co., Ltd
Oh minsun, +82 2 3438
0653
Director
msoh@stc365.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Asahi Kasei and Nara Medical University Confirm 226 nm UVC LED Efficacy Against SARS-CoV-2 and Verify Reduced Effect on Animal Skin Cells
  • HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic
  • Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
  • アジェンディアのマンマプリント検査、NSABP B-42試験で長期内分泌療法の利点を予測する能力を初めて示す
  • アマゾンと全米安全評議会が米国で最も多い労働災害の解決に向け、この種で初となる提携関係を構築